BIO and ViS Research Institute have partnered to expedite and enhance the efficiency of pediatric-drug
development. The deal will allow BIO and its members to use the institute's online analytics platform to assess the capabilities of thousands of disease-specific research centers globally and identify suitable patients. The use of Big Data can make it faster and easier to conduct pediatric clinical studies, BIO President and CEO Jim Greenwood said.

Full Story:
PharmaTimes (U.K.)

Related Summaries